[go: up one dir, main page]

EE200300100A - Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon - Google Patents

Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon

Info

Publication number
EE200300100A
EE200300100A EEP200300100A EEP200300100A EE200300100A EE 200300100 A EE200300100 A EE 200300100A EE P200300100 A EEP200300100 A EE P200300100A EE P200300100 A EEP200300100 A EE P200300100A EE 200300100 A EE200300100 A EE 200300100A
Authority
EE
Estonia
Prior art keywords
polypeptide
vector
making
nucleic acid
pharmaceutical composition
Prior art date
Application number
EEP200300100A
Other languages
English (en)
Inventor
Pfizenmaier Klaus
W�st Thomas
Moosmayer Dieter
Grell Matthias
Scheurich Peter
Original Assignee
Prof. Dr. Klaus Pfizenmaier
Universit�T Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prof. Dr. Klaus Pfizenmaier, Universit�T Stuttgart filed Critical Prof. Dr. Klaus Pfizenmaier
Publication of EE200300100A publication Critical patent/EE200300100A/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200300100A 2000-09-15 2001-09-17 Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon EE200300100A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045592A DE10045592A1 (de) 2000-09-15 2000-09-15 Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
PCT/EP2001/010730 WO2002022833A1 (de) 2000-09-15 2001-09-17 Fusionsprotein aus antikörper-zytokin-zytokin inhibitor (selektokin) als zielspezifisches prodrug

Publications (1)

Publication Number Publication Date
EE200300100A true EE200300100A (et) 2005-02-15

Family

ID=7656260

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300100A EE200300100A (et) 2000-09-15 2001-09-17 Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon

Country Status (22)

Country Link
US (1) US20040053829A1 (et)
EP (1) EP1317556A1 (et)
JP (1) JP2004508828A (et)
KR (1) KR20030048041A (et)
CN (1) CN1214115C (et)
AU (1) AU2001293819A1 (et)
BG (1) BG107613A (et)
BR (1) BR0113928A (et)
CA (1) CA2422759A1 (et)
DE (1) DE10045592A1 (et)
EE (1) EE200300100A (et)
HR (1) HRP20030192A2 (et)
HU (1) HUP0301693A3 (et)
IL (1) IL154185A0 (et)
MX (1) MXPA03002229A (et)
NO (1) NO20031185L (et)
PL (1) PL360540A1 (et)
RU (1) RU2003106429A (et)
SK (1) SK2812003A3 (et)
WO (1) WO2002022833A1 (et)
YU (1) YU18903A (et)
ZA (1) ZA200302008B (et)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002043773A2 (en) * 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
PE20021080A1 (es) * 2001-04-12 2003-02-12 Boehringer Ingelheim Int Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
DE10247755B4 (de) * 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
WO2004069876A2 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring t cell response
US7374898B2 (en) * 2004-10-12 2008-05-20 The Research Foundation Of State University Of New York Peptide inhibitors against seprase
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
DE102005036542A1 (de) * 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
EP1972350A1 (en) * 2007-03-20 2008-09-24 Rijksuniversiteit Groningen Dual targeting system
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
US8895702B2 (en) 2008-12-08 2014-11-25 City Of Hope Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CN102481341B (zh) * 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
EP3762406A2 (en) * 2018-03-09 2021-01-13 Askgene Pharma, Inc. Cytokine prodrugs
SG11202011308VA (en) 2018-05-14 2020-12-30 Werewolf Therapeutics Inc Activatable cytokine polypeptides and methods of use thereof
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
WO2020023702A1 (en) * 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US20220002370A1 (en) * 2018-09-27 2022-01-06 Xilio Development, Inc. Masked cytokine polypeptides
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
EP3983432A1 (en) 2019-06-12 2022-04-20 Askgene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
US20220289822A1 (en) * 2019-08-21 2022-09-15 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
AU2020353235A1 (en) * 2019-09-28 2022-03-31 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
CN115175926A (zh) 2019-11-14 2022-10-11 狼人治疗公司 可激活细胞因子多肽及其使用方法
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5763733A (en) * 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5614191A (en) * 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
DE19900709A1 (de) * 1999-01-11 2000-07-13 Falkenberg Frank W Eine neue Applikationsform für biologisch wirksame Substanzen zur Anwendung bei Menschen und Tieren

Also Published As

Publication number Publication date
DE10045592A1 (de) 2002-03-28
EP1317556A1 (de) 2003-06-11
ZA200302008B (en) 2004-06-25
YU18903A (sh) 2006-05-25
JP2004508828A (ja) 2004-03-25
SK2812003A3 (en) 2003-11-04
AU2001293819A1 (en) 2002-03-26
PL360540A1 (en) 2004-09-06
RU2003106429A (ru) 2004-08-27
NO20031185L (no) 2003-05-05
KR20030048041A (ko) 2003-06-18
HRP20030192A2 (en) 2005-10-31
HUP0301693A2 (hu) 2003-08-28
CA2422759A1 (en) 2003-03-17
BR0113928A (pt) 2003-07-22
CN1214115C (zh) 2005-08-10
BG107613A (bg) 2003-12-31
WO2002022833A1 (de) 2002-03-21
CN1458977A (zh) 2003-11-26
MXPA03002229A (es) 2005-06-20
IL154185A0 (en) 2003-07-31
HUP0301693A3 (en) 2005-11-28
NO20031185D0 (no) 2003-03-14
US20040053829A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
EE200300100A (et) Polüpeptiid, selle kodeerivat nukleotiidjärjestust sisaldav nukleiinhape, vektor ja peremeesrakk, meetod polüpeptiidi valmistamiseks ning farmatseutiline kompositsioon
WO2002101078A9 (en) Cellulases, nucleic acids encoding them and methods for making and using them
WO2003093306A3 (en) Nucleic acids and proteins from streptococcus groups a & b
EP1409683A4 (en) HELICOBACTER PROTEINS, NUCLEIC ACIDS AND THEIR USE
AU2002239444A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
EP1383871A4 (en) INSULATED HUMAN ENZYMATIC PROTEINS, NUCLEIC ACID MOLECULES ENCODING THESE PROTEINS, AND USES THEREOF
AU2001292326A1 (en) Nucleic acid of novel human kinesin-associated gene, protein encoded by the nucleic acid, peptide fragment thereof and anticancer agents comprising the nucleic acid and the like
EP1383908A4 (en) ISOLATED HUMAN ENZYME PROTEINS, HUMAN ENZYME PROTEIN CODING NUCLEIC ACID MOLECULES, AND USES THEREOF
EP1383877A4 (en) INSULATED HUMAN ENZYMATIC PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYMATIC PROTEINS, AND USES THEREOF
EP1385991A4 (en) HUMAN INSULATED ENZYMATIC PROTEINS, NUCLEIC ACID MOLECULES ENCODING THE SAME AND USES THEREOF
AU2001257287A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU9227301A (en) Novel proteins, genes encoding them and method of using the same
WO2000052176A8 (de) β-HEXOSAMINIDASE SOWIE DIESE KODIERENDE DNA-SEQUENZ AUS CILIATEN UND DEREN VERWENDUNG
EP1383876A4 (en) ISOLATED HUMAN ENZYME PROTEINS, HUMAN ENZYME PROTEIN CODING NUCLEIC ACID MOLECULES, AND USES THEREOF
AU2001292273A1 (en) Novel proteins, genes encoding them and method of using the same
AU2002245128A1 (en) Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
ZA9811211B (en) Isolated nucleic acid molecules which encode TAGE molecules, and useS thereof.
AU2001292769A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2003031639A8 (en) Isolated cryopyrins, nucleic acid molecules encoding these, and use thereof
AU2001292687A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2002223183A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
AU2001289134A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
EP1373294A4 (en) HUMAN ENZYME ISOLATED PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN ENZYME PROTEINS, AND USES THEREOF
AU2003220067A8 (en) Jade nucleic acids, proteins and uses thereof
AU2001266577A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof